MyD88 L265P is one of the most common driver mutations found in B-cell lymphomas and associated with a poor prognosis. L265P mutation occurs frequently in 90% of Waldenström’s macroglobulinemia (WM), 50-80% of IgM monoclonal gammopathy of undetermined significance (IgM-MGUS), and 29% of diffuse large B-cell lymphomas (DLBCL) cases. To date MW and aggressive DLBCL with activated B-cell-like (ABC) subtype remain incurable. Tumor-specific MyD88 L265P mutation represents a useful prognostic marker and a promising target for new therapy approach.

arigo offers MyD88 L265P antibody and human IgM ELISA Kit which are useful to detect L265P mutant and measure IgM level in B-cell lymphomas.


MyD88 L265P antibody [SQab30311] (ARG67041) Human IgM ELISA Kit (ARG80947)
 
Targeting MyD88 L265P-oncogenic signaling
MyD88 L265P mutation promotes oncogenic signaling through activation of BTK, HCK, NFkB and JAK-STAT3. It attracts the interest in therapies by targeting BTK, IRAK1/4, and JAK.  arigo offers research tools to examine NFkB and JAK-STAT3 activity. They are useful solutions to in vitro validate the efficacy of novel therapeutic agents.
 
IkBα antibody
(ARG54710)

NFkB Activation
antibody duo (ARG30248)

JAK2-STAT3 Pathway antibody panel (ARG30351)

JAK2
JAK2 pY1007/Y1008
STAT3
STAT3 pY705

 

Rabbit mAbs for B cells
 
CD19 antibody [SQab1869] (ARG66321) CD20 antibody [SQab1719] (ARG66197)

CD79a antibody
[SQab1743] (ARG66254)
CD45 antibody [SQab1881] (ARG66333) CD38 antibody [SQab20221] (ARG66808)

CD138 antibody
[SQab1741] (ARG66252)

Product Highlight
 
 
 
DBA-ITALIA Srl
Via Umbria 10
20054 Segrate (Milano)
 
info@dbaitalia.it

If you no longer wish to receive these announcements click here